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Abstract
Background: Primary effusion lymphoma is a rare distinct large B-cell neoplasm that is associated with Kaposi’s
sarcoma–associated herpesvirus (KSHV) infection. Over recent years, 9 KSHV-positive/Epstein-Barr virus (EBV)-negative
PEL cell lines have been established.
Methods: Tumor cells were collected from the pleural effusion of a 49-year-old male with AIDS. Cells were grown
in RPMI1640 culture medium supplemented with 10 % fetus bovine serum. Single cell cloning was performed
successfully by a limiting dilution method in a 96-well plate. The cell line obtained was designated SPEL.
Results: SPEL cells showed gourd-shaped morphology with a polarized nucleus, expressing CD38, CD138, and
Blimp-1, but not B cell markers such as CD19 and CD20. Polymerase chain reaction analysis revealed that SPEL cells
were positive for KSHV but negative for EBV. Tetradecanoylphorbol acetate induced expression of KSHV lytic
proteins and the production of KSHV particles in SPEL cells. Subcutaneous inoculation of SPEL cells into severe
combined immunodeficiency mice resulted in the formation of solid tumors. Next-generation sequencing revealed
the 138 kbp genome sequence of KSHV in SPEL cells. Suberic bishydroxamate, a histone deacetylase inhibitor,
induced the expression of KSHV-encoded lytic proteins and cell death in SPEL cells.
Conclusions: A new KSHV-positive and EBV-negative PEL cell line, SPEL was established. This cell line may
contribute to furthering our understanding of the pathogenesis of PEL and KSHV infection.
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Background
Kaposi’s sarcoma–associated herpesvirus (KSHV), or hu-
man herpesvirus 8 (HHV-8), is a member of gamma her-
pesvirus family, first isolated from Kaposi sarcoma
lesions in AIDS patients [1, 2]. KSHV has since also
been detected in certain lymphoproliferative disorders
such as primary effusion lymphoma (PEL) and multi-
centric Castleman disease in AIDS patients [1]. PEL, also
known as body-cavity-based lymphoma, is a rare distinct
large B-cell neoplasm that accounts for about 4 % of all
AIDS-related non-Hodgkin’s lymphomas [3, 4]. Patients
with PEL are often also suffering from human immuno-
deficiency virus (HIV) infection or other immune
deficiencies, such as solid organ transplant recipients
[3, 5, 6]. PEL is typically diagnosed as a lymphoma-
tous effusion in the pleural, pericardial, or peritoneal
cavities, without forming solid tumors [7]. In 30–70 % of
cases, Kaposi sarcoma is a complicating factor. KSHV is
detected in the PEL cells without exception [7], whereas
about 80 % of HIV-positive cases also present latent infec-
tion of Epstein–Barr virus (EBV) [8]. Histologically, PEL
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cells possess large, round to irregular-shaped nuclei
with prominent nucleoli, and a variable amount of
cytoplasm that is deeply basophilic and often vacuo-
lated. PEL cells display a unique immunophenotype
[3] expressing CD45 but not typical B-cell (including
surface and cytoplasmic immunoglobulin, CD19, CD20,
CD79a) and T-cell (CD3, CD4, CD8) markers. Instead,
several markers of lymphocyte activation (CD30, CD38,
CD70, human leukocyte antigen DR) and plasma cell
differentiation (CD138) are usually detected [9, 10].
There is currently no standard treatment available for
PEL. At present, a combination of highly active antiretro-
viral therapy with a CHOP (cyclophosphamide, doxorubi-
cin, vincristine, prednisone)-like regimen is considered the
first-line therapy [5, 6]. However, the prognosis of PEL is
extremely poor with a median survival time of around
6 months and a 1-year survival rate of around 40 % [6].
Established cell lines are useful tools for investigating
pathogenesis and treatment outcomes. Over recent
years, 18 PEL cell lines have been established. Nine of
these were co-infected with KSHV and EBV, while the
other nine cell lines were EBV-negative [11–16]. In
this report, we established a new KSHV-positive/EBV-
negative PEL cell line, and demonstrated activation of
KSHV and cell death in response to exposure to vari-
ous drugs.
Methods
Patient
A 49-year-old Japanese male patient with AIDS was
admitted to the hospital with a high-grade fever, ex-
treme weight loss, and massive bilateral pleural effu-
sion. His CD4 cell count was 31 cells/μL. Serologic
tests showed that the patient was positive for hepa-
titis C and B virus antibody in the serum. Tumor
cells in the pleural effusion were examined for
Giemsa staining and flow cytometry, and finally diag-
nosed as CD20-, CD38+, CD138+, and KSHV-encoded
latency-associated nuclear antigen 1 (LANA-1) + PEL
(Fig. 1a and b).
Establishing the cell line
The study protocol was approved by the Institutional
Review Board, National Institute of Infectious Diseases
(Approval No. 617) and the National Defense Medical
College (Approval No. 2396). Tumor cells were col-
lected from the pleural effusion and grown in
RPMI1640 culture medium supplemented with 20 %
fetus bovine serum (FBS). Supplementation with FBS
was gradually reduced during passage. Finally, SPEL
cells were grown in RPMI1640 culture medium sup-
plemented with 10 % FBS. Single cell cloning was
performed successfully by a limiting dilution method
in a 96-well plate. The cell line obtained was desig-
nated SPEL.
Flow cytometry
SPEL cells were fixed and permeabilized using BD
Cytofix fixation buffer and BD Phosflow perm buffer III
(BD Biosciences Pharmingen, San Diego, CA, USA).
Cells were incubated for 1 h with mouse monoclonal
antibodies, including CD3-ε, CD4, CD10, CD19, CD20,
CD30, CD38, CD45, CD45-RO, CD79a, CD98, CD138,
IgD, Ig κ, Ig λ, LFA1 (BD Biosciences Pharmingen),
MDM2, VCAM (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), IgM (Life Technologies, Carlsbad, CA, USA),
gp80 (Thermo Scientific, Waltham, MA, USA), and
Blimp1 (Cell Signaling Technology, Danvers, MA, USA).
The secondary antibody Alexa Fluor 488-conjugated
anti-mouse IgG (Molecular Probes, Eugene, OR, USA)
was then applied and the cells were incubated for
30 min. The cells were washed with stain buffer (BD
Biosciences Pharmingen) three times and then analyzed
using a flow cytometer (Cyflow counter, Partec, Görlitz,
Germany). Data were analyzed using FlowJo software
(Flow Jo, Ashland, OR, USA).
Cytogenetic analysis
Chromosome slides were prepared using a short-term
culture method. In brief, SPEL cells were suspended in a
petri dish filled with the standard growth medium sup-
plemented with 10 % FBS and 0.02 μg/mL colcemid.
The cells were incubated for 20 min at 37 °C and har-
vested. Karyotype analysis was carried out at different
passages choosing 20 well banded metaphases each time
by Chromocenter (Tottori, Japan).
Immunoglobulin gene rearrangement analysis
Immunoglobulin gene rearrangement analysis was per-
formed by the BioMed2 method as described previously
[17, 18].
Polymerase chain reaction (PCR) analysis of virus
genomes
KSHV and HIV DNA were amplified by conventional
PCR [14]. EBV BNLF-1 DNA was amplified with the
following primers: BNLF-1-forward (5ʹ–GCCAAAAG
CTGCCAGATGGT-3ʹ) and BNLF-1-reverse (5ʹ-ACTGA
TGAGTAAGTATTACA-3ʹ). In addition, more than 160
virus genomes were examined with the multivirus real-
time PCR system as described previously [19].
Immunofluorescence assay
SPEL and BCBL-1 cells were cultured with or without
tetradecanoylphorbol acetate (TPA) for 48 h. Suspended
cells were then cytospun onto a glass slide. The samples
were incubated with rabbit monoclonal antibodies to
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LANA-1, K8, vIL-6, or ORF59 diluted × 1000 with Block
Ace, and mouse monoclonal antibody to replication and
transcription activator (RTA) diluted × 500 with Block
Ace for 1 h at room temperature, followed by incubation
with Alexa Fluor 488-conjugated goat anti-rabbit (or anti-
mouse) IgG (H + L) (Molecular Probes) diluted × 400 with
PBS for 1 h at room temperature [20, 21]. Nuclear staining
was performed with propidium iodide at 5 μg/ml. Imaging
was performed using a fluorescence microscope (IX71,
Olympus, Tokyo, Japan).
Western blot analysis
Protein extraction and immunoblotting were performed
as described previously [22]. Briefly, 1 × 106 cells were
lysed in 100 μL M-PER lysis buffer containing Halt
protease and a phosphatase inhibitor cocktail (Pierce
Biotechnology, Rockford, IL, USA). Cell lysates were
subjected to sodium dodecyl sulfate polyacrylamide gel
electrophoresis and transferred onto a polyvinylidene
fluoride microporous membrane (Immobilon-P Transfer
Membrane, Millipore, Bedford, MA, USA) using the
NuPAGE system (Life Technologies). The membranes
were blocked with Block Ace (DS Pharma Biomedical,
Osaka, Japan) and probed with the antibodies to
LANA-1 [23], RTA [21], vIL-6 [20], ORF59 [24], or
Lyn (H-6, sc-7274, Santa Cruz Biotechnology), followed
by a horseradish peroxidase-conjugated anti-mouse
antibody (Promega, Madison, WI, USA) with an im-
munoreaction enhancer solution (Can Get Signal,
Toyobo, Osaka, Japan). Blots were visualized using
Super-Signal West Femto Chemiluminescent Substrate
(Thermo Fisher Scientific).
Northern blotting
SPEL and BCBL-1 cells were cultured with or without
TPA for 48 h. Total RNA was extracted from cells using
Fig. 1 Morphology of SPEL cells and the corresponding original tumor cells. a, b Lymphoma cells in the pleural effusion of the patient. Giemsa
staining (a) and an immunofluorescence assay for KSHV-encoded LANA-1 (b) are shown. c Giemsa staining of SPEL cells. d Phase-contrast image
of SPEL cells in the culture medium. e Transmission electron microscopy of SPEL cells. f–h Immunofluorescence assay for LFA1 (BD Biosciences
610826, f), caveolin (Abcam ab2910, g), and transferrin receptor (TfR, 13-6800, Zymed Laboratories, South San Francisco, CA, USA, h) in SPEL cells
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the Isogen RNA extraction kit (Nippon Gene, Tokyo,
Japan). Then, 10-μg mRNA samples were separated on a
1.9 % formaldehyde-containing agarose gel, transferred
to a nylon membrane (Roche Molecular Biochemicals,
Indianapolis, IN, USA), and hybridized with K8 and
β2-microglobulin probes. The probes were labeled by
PCR with digoxigein-11-dUTP (Roche Molecular
Biochemicals) [25].
Quantitative real-time PCR
SPEL and BCBL-1 cells were cultured with or without
TPA for 48 h. DNA and RNA were extracted from
the cells using the DNeasy Blood & Tissue Kit and
RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany),
respectively. The KSHV copy number was analyzed by
real-time PCR for ORF26 DNA. The DNA copy num-
bers per cell were calculated by dividing the ORF26
Table 1 Drugs used for screening in SPEL cells
Drug Company, Catalog no. Category Concentration
No drug - Control -
DMSO (Dimethyl sulfoxide) Sigma-Aldrich, 34869 Control -
Doxorubicin Kyowa-Kirin, Adriacin Anti-cancer drug 10 μM
Vincristine Nippon-Kayaku, Oncovin Anti-cancer drug 10 μM
Etoposide Sigma-Aldrich, E1383 Anti-cancer drug 10 μM
Anti-IgM SA-DA4 Abcam, ab99740 Anti-IgM 10 μM
Anti-IgM FC Abcam, ab772 Anti-IgM 10 μM
Anti-IgM UNLB Southern Biotech, 2020-01 Anti-IgM 10 μM
IC-261 Sigma-Aldrich, I0658 Casein kinase inhibitor 10 μM
TBB Sigma-Aldrich, T0826 Casein kinase inhibitor 10 μM
D4476 Sigma-Aldrich, D1944 Casein kinase inhibitor 10 μM
TPA (tetradecanylphorbol acetate) Sigma-Aldrich, P8139 Dicarboxylic acid 20 ng/mL
SBHA (suberic bishydroxamate) R &D Systems, 38937-66-5 HDAC inhibitor 10 μM
Trichostatin A Sigma-Aldrich, T8552 HDAC inhibitor 10 μM
Cl994 Sigma-Aldrich, C0621 HDAC inhibitor 10 μM
SAHA Sigma-Aldrich, SML0061 HDAC inhibitor 10 μM
Tubacin Sigma-Aldrich, SML0065 HDAC inhibitor 10 μM
Scriptaid Sigma-Aldrich, S7817 HDAC inhibitor 10 μM
Panobinostat Sigma-Aldrich, EPI009 HDAC inhibitor 10 μM
Sodium Butyrate Sigma-Aldrich, B5887 HDAC inhibitor 1.25 μM
SC514 Santa Cruz, sc-205504 IKKb inhibitor 10 μM
Thalidomide Sigma-Aldrich, T144 Immunomodulatory drug 10 μM
Pomalidomide Sigma-Aldrich, P0018 Immunomodulatory drug 10 μM
Lenalidomide Santa Cruz, sc-218656 Immunomodulatory drug 10 μM
Cyclophosphamide Sigma-Aldrich, C7397 Immunosuppressant 10 μM
AG490 (Tyrphostin AG 490) Sigma-Aldrich, T3434 JAK inhibitor 10 μM
SP600125 Sigma-Aldrich, S5567 JNK inhibitor 10 μM
Rapamycin Sigma-Aldrich, R8781 mTOR inhibitor 10 μM
BAY11-7082 Sigma-Aldrich, B5556 NF-kB inhibitor 10 μM
LY-294002 Sigma-Aldrich, L9908 PI3K inhibitor 10 μM
Z-leu-leu-leu-H Peptide Institute, 3175-v Proteasome inhibitor 10 μM
Bortezomib Calbiochem, 5.04314.0001 Proteasome inhibitor 10 μM
Simvastatin MSD, Lipovas Statin 10 μM
Lovastatin Sigma-Aldrich, 1370600 Statin 10 μM
Prednisolone Shionogi, Predonine Steroid 10 μM
Dexamethasone Sigma-Aldrich, D4902 Steroid 10 μM
Osawa et al. Infectious Agents and Cancer  (2016) 11:37 Page 4 of 15
copy numbers by half of the beta-actin copy numbers,
because each cell had two copies of the gene in two
alleles. KSHV mRNA transcripts were also detected
by real-time reverse-transcription (RT)-PCR of RTA,
which is expressed in the immediate early phase of
KSHV infection. Primer and probe sequences for
ORF26 and RTA have been reported previously [26, 27].
Real-time PCR or RT-PCR were performed on an
Mx3005P PCR system (Agilent Technologies, Santa Clara,
CA, USA).
KSHV real-time PCR array
SPEL and BCBL-1 cells were cultured with or with-
out TPA for 48 h. RNA samples were extracted using
an RNeasy Mini Kit (Qiagen). To determine the ex-
pression profiles of KSHV gene transcripts, a KSHV
real-time PCR array was performed using the TaqMan
real-time RT-PCR system according to a previous
report [22]. This system was designed to analyze all
of the 87 KSHV gene transcripts simultaneously.
Each value was normalized to the copy number of
GAPDH transcripts, and the ratio of the values for
treated (TPA for 48 h) versus untreated cells was
calculated.
Electron microscopy
TPA-treated SPEL cells were pelleted by centrifuga-
tion, fixed with 2.5 % glutaraldehyde and 2 % parafor-
maldehyde in 0.1 M phosphate buffer (pH 7.4) for
2 h at room temperature, post-fixed in 1 % osmium
tetroxide and embedded in Epon. Ultrathin sections
were stained with uranyl acetate and lead citrate, and
observed under a transmission electron microscope
(H7700, Hitachi High Technologies, Tokyo, Japan) at
80 kV.
Whole-genome sequencing of KSHV using a
next-generation sequencer
KSHV particles were collected from 75 mL of culture
supernatant of 10 μM of suberic bishydroxamate
(SBHA)-stimulated SPEL cells. The culture supernatant
was subjected to ultracentrifugation at 100,000 × g for
2 h. The pellet was treated with DNase and RNase for
1 h. After heat inactivation at 70 °C for 10 min, viral
DNA was extracted from the pellet. A DNA library was
prepared with KAPA HyperPlus kit (Kapa Biosystems,
Wilmington, MA, USA) with five cycles of PCR enrich-
ment, followed by gel extraction for purification of
the DNA library. Next-generation sequencing was
Fig. 2 Flow cytometry of SPEL cells. Red and blue lines indicate specific and control antibodies, respectively
Osawa et al. Infectious Agents and Cancer  (2016) 11:37 Page 5 of 15
Fig. 3 Chromosomal karyotype of SPEL cells. An image of the Q-band is shown
Fig. 4 Genetic rearrangement of the immunoglobulin κ chain as analyzed by the BioMed2 method. a SPEL cell line. b Peripheral blood mononuclear
cells (PBMC) from another unrelated patient. Fragment analysis of PCR products of the IGK tube A using the BioMed 2 method is shown. PCR products
of Vk1f/6/Vk7-Jk, Vk3f-Jk, and Vk2f/Vk4/Vk5-Jk were observed in the 120–160, 190–210, and 260–300 bp regions, respectively. Arrows indicate clonal
bands. Arrow heads indicate products of the germ bands in each region
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performed using a MiSeq Reagent Kit v3 (600-cycle;
Illumina, San Diego, CA, USA). Sequence reads were
trimmed and assembled using the VirusTAP pipeline
software (https://gph.niid.go.jp/cgi-bin/virustap/index.cgi)
[28]. Sequence gap regions were amplified by conventional
PCR, and sequenced using the Sanger method. The
complete genome sequence of SPEL KSHV was de-
posited in the GenBank database under accession no.
AP017458.
Multiple sequence alignments and the KSHV genotype
Comparative KSHV full genome analysis was performed
using the progressive alignment option available in the
Mauve software (version 20150226, Darling Laboratory
at the University of Technology Sydney). Four KSHV
genomes, GK18 (GenBank accession no. AF148805.2),
BCBL-1 (HQ404500.1), DG-1 (JQ619843.1), and JSC-1
(GQ994935.1), were compared with the SPEL KSHV
sequence. Nucleotide sequences of the KSHV K1 re-
gion were aligned and a phylogenetic tree was con-
structed using the NJ-plot method and the Genetyx
software (Genetyx, Tokyo, Japan). In addition to our
samples, 17 previously reported K1 sequences were
obtained from the GenBank database and used as ref-
erence sequences for comparison with the sequences
in this study [29].
Inoculation of the SPEL cell line into severe combined
immunodeficiency mice
SPEL cells (5 × 107) were subcutaneously injected into
the neck of three 10-week-old CB17 severe combined
immunodeficiency (SCID) mice [27]. All procedures
were approved by the Animal Care and Use Committee
of the National Institute of Infectious Diseases (NIID,
Approval No 115123) and were conducted according to
the ‘Guidelines for Animal Experiments Performed at
the NIID’.
Fig. 5 PCR analysis of virus infection in SPEL cells. KSHV ORF26,
the EBV BNLF-1 region, and the HIV gag gene were amplified
by conventional PCR. The human beta-globin gene was included
as an internal control. TY1 and BCBL1 are KSHV-positive, EBV-
negative, cell lines. Raji is an EBV-positive Burkitt lymphoma cell
line. A plasmid containing the HIV-gag region was used as a
HIV control
Fig. 6 Expression of KSHV-encoded protein in TPA-stimulated SPEL cells. a Immunofluorescence assay for KSHV-encoded proteins. PI (propidium
iodide) was used as a counter stain for the nucleus. b Western blot analysis. Lysates of 0, 24, and 48 h-TPA stimulated PEL cells were electrophoresed
and blotted
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Histology and immunohistochemistry
Histological analysis and immunohistochemistry for
LANA-1 was performed as described previously [27].
Drug screening
SPEL cells were cultured with eight histone deacetylase
(HDAC) inhibitors (SBHA and HDAC inhibitor Set II:
Sigma Aldrich, St Louis, MO, USA) and 26 other antitu-
mor drugs (Table 1) for 48 h. Cells were stained with
trypan blue and cell viability was measured using a
TC10 automated cell counter (BioRad, New York, NY,
USA). Simultaneously, RNA was extracted from the
drug-stimulated cells, and RTA and GAPDH mRNA
copies were measured by real-time RT-PCR [27].
Results
Establishment of the SPEL cell line and its morphological
features
At first, the primary culture of the tumor cells from the
pleural effusion grew in RPMI1640 culture medium sup-
plemented with 20 % FBS. However, after a few passages,
autonomous growth was observed in RPMI1640 culture
medium with 10 % FBS. The 30th passage was accom-
plished on the 150th day of culturing. After single cell
Fig. 7 KSHV-encoded mRNA was induced by TPA in SPEL cells. a Real-time PCR analysis to determine the number of KSHV copies per cell in two
TPA-stimulated cell lines. b Real-time RT-PCR analysis of the mRNA level of RTA in TPA-stimulated cells. c Northern blot analysis of KSHV-encoded
transactivator protein, K8 (upper panel), and the human beta-2 microglobulin gene (B2M, lower panel). d KSHV real-time PCR array. The Y axis indicates
the expression ratio to non-stimulated cells. KSHV-encoded mRNAs are listed in the graph in order of their expression levels in BCBL1 cells
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cloning, cells showed a gourd-shaped morphology with a
polarized nucleus (Fig. 1). Single cloned cells were desig-
nated as SPEL (Saitama-PEL). Electron microscopy also
demonstrated that the polarized cytoplasm in the gourd-
shaped SPEL cells contained abundant mitochondria
and Golgi apparatus (Fig. 1e). An immunofluorescence
assay revealed that caveolin and transferrin receptor lo-
calized predominantly in the polarized cytoplasm,
whereas LFA1 was expressed broadly (Fig. 1f–h).
Immunological and genetic characteristics of SPEL cells
Flow cytometry analysis revealed that SPEL cells were
positive for CD30, CD38, CD138, CD4, CD45 and
Blimp-1, LFA1, MDM2, IL-6, VCAM, MyD88, gp80,
IgD, IgM, IgG, and Ig light chain κ, and negative for
CD3, CD10, CD19, CD20, CD45RO, CD79a, CD98, and
Ig light chains λ (Fig. 2). These immunophenotypic fea-
tures suggested that SPEL cells were derived from the
plasma cell lineage. Chromosomal analysis revealed that
the karyotype of SPEL cells was 46, XY, +del(7)(q32), +8,
der(8)t(8;8)(p21;q13)ins(8;?)(p21;?) × 2, 13, add(15)(p11),
der(21;22)(q10;q10)) (Fig. 3). BioMed2 analysis [17]
revealed that SPEL cells had an immunoglobulin κ gene
rearrangement, indicating the B cell lineage (Fig. 4). PCR
analysis of the DNA of SPEL cells clearly indicated that
they are a KSHV-positive, EBV-negative PEL cell line
(Fig. 5). The multivirus real-time RT-PCR system [19]
showed that SPEL cells were positive for KSHV but
negative for more than 160 other viruses including EBV,
HIV-1, hepatitis B virus, and hepatitis C virus (data not
shown).
Induction of KSHV lytic infection in SPEL cells by TPA
An immunofluorescence assay and western blot analysis
demonstrated that TPA induced expression of RTA and
other early lytic proteins encoded by KSHV, such as
vIL-6, K8, and ORF59, in SPEL and BCBL-1 cells
(Fig. 6). The localization of lytic proteins was consistent
with the findings in other KSHV-positive cell lines [20].
The addition of TPA to the culture medium significantly
increased viral DNA copy compared with non-treated
cells (Fig. 7a). Real-time RT-PCR demonstrated an in-
crease in the mRNA copy number of KSHV-encoded RTA
in TPA-stimulated SPEL cells as well as in BCBL1 cells
Fig. 8 Transmission electron microscopy of KSHV particles in TPA-stimulated SPEL cells. a Virus capsids in the nucleus. Virus capsids are indicated
by arrows. b Low power image of the cell. Virus capsids were observed in the nucleus (arrows) and arrow heads indicate enveloped virus particles
in the cytoplasm. Bars indicate the scale
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(Fig. 7b). Northern blot analysis showed that TPA induced
the expression of K8 mRNA, an early gene of KSHV in
SPEL cells (Fig. 7c). We also investigated the expression
profiles of KSHV-encoded gene transcripts using a real
time RT-PCR array that detected KSHV gene transcripts.
The expression profiles of KSHV gene transcripts in SPEL
cells were similar to those in BCBL-1 cells (Fig. 7d). Fi-
nally, electron microscopic analysis revealed an increased
number of enveloped viral particles in the cytoplasm and
viral capsid in the nucleus of TPA-stimulated SPEL cells
(Fig. 8). These data indicated that KSHV lytic infection
was induced by TPA stimulation in SPEL cells as well as
in another KSHV-positive PEL cell line, BCBL1.
KSHV genome sequence analysis in SPEL cells
KSHV particles were collected from the supernatant of
stimulated SPEL cells, and the DNA of KSHV was sub-
jected to deep sequencing using a next-generation se-
quencer. The complete genome of KSHV in SPEL cells
was found to be 137,988 bp in length and contain
terminal repeats. Compared with the reference sequence
of KSHV (strain GK18), nucleotide variations were iden-
tified with other representative KSHV strains (Fig. 9a).
Internal repeat regions in the DNA from SPEL cells
(between K4.2 and K5, ORF69 and ORF71, and internal
repeat in LANA-1) were unique compared with other
strains. Two single nucleotide polymorphism (SNP) sites
were identified in the exon of ORF56 (G/C nt 80190)
and between ORF57 and vIRF1 (A/G nt 83625). The
SNP in ORF56 leads to a non-synonymous mutation,
with a change of a glycine or histidine in the 257 pos-
ition of the protein. A phylogenetic tree based on the se-
quence of the K1 region showed that KSHV from SPEL
cells belonged to genotype A, along with the original
PEL cells of the patient and other AIDS-associated PEL
and Kaposi’s sarcoma patients in Japan (Fig. 9b).
Tumor formation in SCID mice by inoculation of SPEL cells
To investigate tumor formation in vivo, SPEL cells were
inoculated into the posterior cervical region of three
Fig. 9 Full genome sequencing of KSHV from SPEL cells. a Distribution of nucleotide variations across the KSHV genome compared with the
reference sequence GK18. Nucleotide similarity is indicated by red lines. Annotated open reading frames are shown as white rectangles below
the similarity bars. This figure was generated using Mauve software. b Phylogenetic tree of the KSHV K1 region. SPEL cells and their origin cells
(15-027) are indicated by small black circles, both belong to group A
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SCID mice. After 4–5 weeks, solid tumors 2–3 cm in
diameter were observed at the inoculation site of each
mouse (Fig. 10). Tumors also occurred in the back in
two mice, and near the face in one mouse. Pathological
analysis revealed that these tumors consisted of large
diffuse lymphoma cells. LANA-1 was detected in the nu-
cleus of almost all of the tumor cells by immunohisto-
chemistry. Real-time PCR demonstrated that the KSHV
and human β-actin DNA counts were similar to those in
SPEL cells (Fig. 10b). These data provided evidence that
all of these tumor cells were derived from SPEL cells.
Cells derived from the resected tumors of SCID mice
were cultured in RPMI1640 medium with 10 % FBS.
The cells showed autonomous growth in the culture
medium for at least four months, and were characterized
as LANA-1-positive lymphoma cells with a gourd-
shaped morphology, indicating that the cells originated
from SPEL cells (Fig. 10e and f).
HDAC inhibitors induced KSHV replication in SPEL cells
To test the effect of various drugs on SPEL cells, 34
drugs were individually added to SPEL cells and the cells
were cultured for 48 h. A cell viability test demonstrated
that SBHA, an HDAC inhibitor, induced cell death in
SPEL cells in a similar way to other anti-cancer drugs
such as doxorubicin and vincristine (Fig. 11a). SBHA
also induced the expression of RTA transcripts in SPEL
cells, as seen for other HDAC inhibitors such as tacedi-
naline (CI-994), and panobinostat (LBH589) (Fig. 11b
and data not shown). The copy number of ORF26 was
Fig. 10 Tumor formation mediated by SPEL cells in vivo. a Macroscopic view of SPEL-inoculated SCID mice 4 weeks after inoculation. Mice in the
middle and right displayed solid tumors at the inoculation sites (arrows). The mouse on the left was the control with no inoculation. b Analysis of
the number of KSHV genome copies in the solid tumors of SCID mice and SPEL cells by real-time PCR. Error bars indicate the standard deviations.
c, d HE staining (c) and immunohistochemistry for LANA-1 (d) of the resected tumors from SCID mice. e, f Giemsa staining (e) and
immunofluorescence for LANA-1 of cultured cells from SCID tumors (e)
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also increased in both cell lines stimulated with SBHA
and panobinostat (data not shown). These data sug-
gested that HDAC inhibitors may contribute to the kill-
ing of tumor cells by inducing KSHV lytic infection
from a latent infection in these cells.
Discussion
In the present study, we established a new KSHV-
positive and EBV-negative PEL cell line, SPEL. To date,
10 KSHV-positive/EBV-negative PEL cell lines have been
reported including SPEL (Table 2) [11–16]. The mor-
phological features of SPEL cells, a gourd-shaped form
with a polarized nucleus, were quite different from those
of previous cell lines. This morphology was maintained
after inoculation into SCID mice. Although the histo-
logical features of solid tumors in SCID mice showed
diffuse large cell morphology similar to diffuse large B-
cell lymphoma cells, culture cells established from
resected tumors from the SPEL-inoculated SCID mice
demonstrated a gourd-shaped form similar to SPEL cells.
This suggested that the gourd-shaped form was associ-
ated with SPEL cell growth in effusion. The cytoplasm of
SPEL cells contains abundant mitochondria and Golgi
apparatus. In addition, the polarized localization of
Fig. 11 Drug screening for cell death and KSHV activation in SPEL cells. a Cell viability at 48 h after the addition of a drug to the culture medium.
b Expression ratio of RTA to GAPDH mRNA at 48 h after the addition of a drug to the culture medium by real-time RT-PCR. Detailed information
regarding the drugs and concentrations used are listed in Table 1
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caveolin, an integral membrane protein associated with
caveolae, and transferrin receptor were observed in the
cytoplasm of SPEL cells, suggesting that such morpho-
logical features may be associated with protein produc-
tion and signal transduction in these cells.
The complete genome of KSHV from SPEL cells was
sequenced in this study. Although several full KSHV ge-
nomes have previously been deposited in the GenBank
database, none of these originated from Asia. Phylogen-
etic tree analysis based on the K1 region revealed that
SPEL KSHV belongs to genotype A. Nucleotide varia-
tions, including SNPs and different repeat numbers in
the repeat region, were detected in SPEL KSHV com-
pared with the genome sequence of another genotype A
strain of KSHV, BrK.219 (accession no. KF588566).
However, chemical stimulation with TPA was able to in-
duce activation and replication of KSHV, suggesting that
the nucleotide variations identified in SPEL KSHV did
not affect viral activation.
It has been reported that several chemical and bio-
logical agents induce the viral lytic cycle in PEL cell lines
[15, 22, 30], the best studies of which are TPA [15] and
HDAC inhibitors [30]. HDACs are enzymes that have
the ability to remove acetyl groups from ε-N-acetyl ly-
sine amino acids in histones and other proteins. HDACs
are critical regulators of both nuclear and cytoplasmic
processes, including transcriptional initiation and elong-
ation, protein stability, and multi-protein complex for-
mation [31–34]. In recent years, HDACs have been
intensively investigated as therapeutic targets because of
their important role in gene expression. Some HDAC in-
hibitors such as sodium butylate, valproic acid, trichosta-
tin A, nicotinamide, and sirtinol have been reported to
induce viral replication in PEL cell lines [30, 35].
Although the mechanism of action of HDAC inhibitors
in PEL cells have yet to be fully elucidated, HDAC
inhibitors are thought to play multiple roles in expressing
RTA of KSHV, which leads to viral DNA replication and
the release of mature virions, resulting in tumor
destruction [35]. In our experiments, SBHA strongly in-
duced KSHV lytic replication in SPEL cells and decreased
cell viability compared with other HDAC inhibitors. A limi-
tation of our experiments was that we were unable to clar-
ify whether the cytotoxicity in SPEL cells was due
predominantly to viral lytic re-activation or the induction
of apoptosis. Despite this, the establishment of the SPEL
cell line may further our understanding of the pathogenesis
of PEL and the therapeutic mechanism of action of HDAC
inhibitors in KSHV-related malignancies.
Conclusions
A new KSHV-positive and EBV-negative PEL cell line,
SPEL was established. SPEL cells showed gourd-shaped
morphology with a polarized nucleus. TPA and SBHA, a
HDAC inhibitor, induced expression of KSHV lytic proteins
and the production of KSHV particles in SPEL cells. Next-
generation sequencing revealed the 138 kbp genome se-
quence of KSHV in SPEL cells. This cell line may contrib-
ute to furthering our understanding of the pathogenesis of
PEL and KSHV infection.
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